From Downstream Products to Four Applications
It starts with the products. PAN-Biotech's downstream range - concentrated buffers and stock solutions, DMF-backed utilities and WFI Beyond - is the foundation four modalities are built on. Each one covered in full, from upstream culture to downstream drug substance, on a single GMP-grade range.
One shared core, four applications covered in full
PAN-Biotech built the downstream range first - the concentrated buffers, universal stock solutions, DMF-backed utilities and WFI Beyond that every purification and formulation step depends on. Downstream is where the modalities converge: monoclonal antibodies, cell & gene therapy, vaccines and mRNA all run on the same buffer chemistry. From that shared core outward, PAN covers each application in full - upstream media and supplements included - so a whole process comes from one manufacturer, one quality system, one regulatory framework.
Select a modality
Each modality is covered in full - upstream through downstream - on the same GMP-grade range. All four processes are live now.
In depth, per application. Edition A02 · Monoclonal antibodies · Edition A03 · Cell & gene therapy · Edition A04 · mRNA · Edition A05 · Vaccines - and for the shared core, Edition D01 · Downstream and D02 · Water. All editions: In-Depth Industry Editions.
The shared downstream core
The reason one range covers four applications is that they lean on the same downstream products. A small set of concentrated stock solutions - WFI, DPBS, NaCl 5 M, Tris-HCl, phosphate, acetate, histidine and citrate - recurs across every workflow; filed FDA Drug Master Files sit behind DPBS and WFI; and every downstream buffer can be taken beyond compendial with WFI Beyond. Add the upstream media and supplements for each modality, and the coverage is complete.
Whitepapers & technical papers
The Open Downstream
Why downstream is where cost, quality and regulatory risk concentrate - and how owning the options takes the risk off the table.
Read the paperBeyond Compendial - Buffers & Reagents
The impurity dossier - elemental impurities, residual solvents, nitrosamines, leachables - mapped to mAb, mRNA, cell & gene and vaccine.
Read the paperFrom Bench to GMP
The make-versus-buy decision for process buffers - the five hidden costs of staying in-house at GMP scale, and how to organise the switch.
Read the paperWFI Beyond
Water for Injection engineered beyond the compendial monograph - the opt-in quality ceiling under every buffer, in every modality.
Read the paper